LOGIN  |  REGISTER
Surmodics

BioRestorative Therapies (NASDAQ: BRTX) Stock Quote

Last Trade: US$1.38 -0.01 -0.91
Volume: 33,840
5-Day Change: 1.47%
YTD Change: -20.69%
Market Cap: US$9.050M

Latest News From BioRestorative Therapies

MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 at the Ritz Carlton, Laguna Niguel in Dana Point, California BioRestorative’s Chief Executive Officer, Lance Alstodt, is scheduled... Read More
MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 3,351,580 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $2.33 per... Read More
Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial Company to host webcasted conference call today at 8:30am EST MELVILLE, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the public availability of a poster, presented... Read More
Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation Company to host webcasted conference call to review data on February 5, 2024 at 8:30am EST MELVILLE, N.Y., Feb. 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that... Read More
Notice of allowance will be the fourth U.S. patent granted under Company’s ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes MELVILLE, N.Y., Dec. 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and... Read More
MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the ROTH MKM Healthcare Opportunities Conference. Company BioRestorative Therapies, Inc. Presenter Lance Alstodt, Chief Executive Officer Date & Time... Read More
BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to Supply Biologics for Cosmetic Applications in Strategic Agreement Agreement Represents Initial Venture into the $62.8 Billion Global Aesthetics Market Initial Order of 5,000 Vials of Product Represents Controlled Launch and Will Have Positive Financial Impact MELVILLE, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.... Read More
Site activation allows for patients in the State of New York to participate in the BRTX-100 tria 15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects MELVILLE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that Northwell Health, New... Read More
MELVILLE, NY / ACCESSWIRE / July 31, 2023 / Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to the National Institute of Neurological Disorders and Stroke, approximately 80% of adults will experience back pain at some point. BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative") recently held a virtual panel about their stem cell-based therapies and... Read More
MELVILLE, NY / ACCESSWIRE / July 21, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative"), a clinical-stage company specializing in stem cell-based therapies, has announced that it has been granted a license by the New York State Department of Health to operate as a tissue bank. The license enables BioRestorative to process mesenchymal stem cells obtained from autologous donors. BioRestorative is now the... Read More
MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into a definitive agreement with several accredited and institutional investors for the sale of 685,033 shares of the Company’s common stock at an offering price of $3.03 per share in a... Read More
MELVILLE, NY / ACCESSWIRE / July 7, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumbar disc disease, BRTX-100. The independent review body Data Safety Monitoring Board (DSMB) which is overseeing dose and safety related issues during the course of the trial approved the trial's continuation with no changes to the current... Read More
No D ose L imiting T oxicity (DLT) w as O bserved in the P atients in the S afety R un- I n S egment of S tudy DSMB R ecommendation A llows f or O pen E nrollment MELVILLE, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the independent Data Safety Monitoring... Read More
MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22 nd at 9:00 A.M.... Read More
Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100 MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that the final subject in its BRTX-100 Phase 2 clinical trial safety... Read More
MELVILLE, NY., June 01, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Healthcare Conference being held June 7-9, 2023 at the Marriot Marquis in New York. Senior management will also be available for one-on-one investor meetings... Read More
License will enable expanded clinical operations for investigator-initiated trials and potential “right to try” uses of BRTX-100 MELVILLE, N.Y., May 31, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has received a license from the New York State Department of Health to... Read More
Upon issuance , patent will be the fourth Japanese patent to issue for the ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes MELVILLE, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the Japanese Patent and Trademark... Read More
MELVILLE, NY / ACCESSWIRE / May 12, 2023 / Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike. BADSC therapy is a novel and proprietary form of regenerative medicine that is used to address several medical conditions , including metabolic disorders such as Obesity, Type 2 Diabetes,... Read More
New York State’s largest health care provider will participate in BRTX’s clinical trial Expansive universe of patients and clinical sites from which to recruit high quality subjects Leverage Northwell’s “Center for Regenerative Orthopedic Medicine” Potential future collaborations to be explored in connection with basic science research MELVILLE, N.Y., May 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.... Read More
MELVILLE, NY., May 04, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Inaugural EF Hutton Global Conference taking place May 10 th to 11 th at the Plaza Hotel in New York City. The Inaugural EF Hutton Global Conference is a two-day,... Read More
Clinical data from safety run-in scheduled to be released in second half of 2023 MELVILLE, N.Y., April 24, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it has completed enrollment for the safety run-in component of its Phase 2 clinical study of BRTX-100 targeting... Read More
Bruder Consulting & Venture Group engaged to expand BRTX-100 c linical indication p ipeline MELVILLE, N.Y., March 13, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it has entered into an agreement with the Bruder Consulting & Venture Group (“BCVG”), a full service... Read More
Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or body fat. A metabolic disorder can occur when the body's chemical reactions become abnormal. This results in metabolic syndrome, where there is an excess or scarcity of health-preserving essential substances. Metabolic syndrome... Read More
Melville, NY., March 07, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate at the Roth 35 th Annual Conference being held from March 12 – 14 at The Ritz Carlton, Laguna Niguel in Dana Point, California. Lance Alstodt, President and CEO... Read More
Notice of allowance will be the third US patent to issue from this ThermoStem ® family targeting obesity and metabolic disorders, including type 2 diabetes MELVILLE, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office... Read More
Patent provides protection in key international markets for BioRestorative ’ s ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes MELVILLE, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has... Read More
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. The company is engaged in developing therapeutic products using cell and tissue protocols, primarily with adult stem cells, for large multi-billion dollar markets that are underserved and affect millions of Americans, like chronic lower back pain and metabolic disorders. BioRestorative currently has two... Read More
Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones MELVILLE, N.Y., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company” ) (NASDAQ : BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to the Company for... Read More
Astria Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB